FAQ on Quantum BioPharma Ltd.'s $600K Private Placement and Company Overview

What is Quantum BioPharma Ltd. seeking shareholder approval for?

Quantum BioPharma Ltd. is seeking shareholder approval for a non-brokered private placement of class A multiple voting shares (MVS) for gross proceeds of up to $600,000 at its annual general and special meeting on September 26, 2025.

How will the proceeds from the private placement be used?

The proceeds from the private placement will be used for general working capital purposes.

What is the significance of the private placement for Quantum BioPharma Ltd.?

The private placement is significant as it provides the company with necessary funding to support its operations and continue its focus on developing innovative biotech solutions for challenging disorders.

Who is expected to subscribe to the private placement?

The Offering is expected to be fully subscribed by existing MVS holders.

What are the hold period terms for the securities issued in the private placement?

All securities will be subject to a four-month-plus-one-day hold period under Canadian securities laws.

What is Quantum BioPharma Ltd.’s focus area?

Quantum BioPharma Ltd. is focused on building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders.

What is Lucid-MS, and why is it important?

Lucid-MS is Quantum BioPharma’s lead compound, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.

How does Quantum BioPharma Ltd. benefit from unbuzzd(TM)?

Quantum BioPharma retains ownership of 20.11% of Unbuzzd Wellness Inc. and receives royalty payments of 7% of sales from unbuzzd(TM) until payments total $250 million, then 3% in perpetuity, while retaining rights to develop similar products for pharmaceutical and medical uses.

Where can investors find the latest news and updates about Quantum BioPharma Ltd.?

The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM.

What is InvestorWire, and how is it related to Quantum BioPharma Ltd.?

InvestorWire is a specialized communications platform that provides advanced wire-grade press release syndication for private and public companies, including Quantum BioPharma Ltd., to efficiently reach target markets and demographics.